Top Tweets for #hpots

The article outlines the EDS-POTS-MCAS trifecta, a phenotype in hypermobile patients previously misdiagnosed as anxiety, chronic fatigue, or fibromyalgia. This involves young, often female patients with hypermobility, dysautonomia, GI dysfunction, food intolerances, palpitations, and flares. Hypermobile Ehlers-Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD) is a connective tissue disorder affecting collagen integrity in joints, skin, blood vessels, and organ-supporting tissues. Postural Orthostatic Tachycardia Syndrome (POTS) is autonomic dysfunction with heart rate rise ≥30 bpm on standing (≥40 bpm in adolescents) without orthostatic hypotension, plus symptoms. Mast Cell Activation Syndrome (MCAS) involves inappropriate mast cell mediator release causing multisystem symptoms. Overlaps include roughly 80% of hEDS patients having POTS, approximately 31% of POTS patients having hEDS, and about 31% MCAS prevalence in patients with both POTS and EDS versus 2% without. These reflect mechanistic links. Mechanisms: Weak collagen scaffold in blood vessels alters elasticity, increases venous distensibility, causes gravity-dependent blood pooling, and prompts autonomic compensation via sympathetic hyperdrive, yielding tachycardia, fatigue, and lightheadedness. Mast cells, embedded in connective tissue, face altered mechanical and biochemical environments from defective collagen, predisposing to activation. Recent 2025 proteomics in hEDS shows reduced complement proteins, indicating an intrinsic immune component. Mast cell mediators like histamine raise sympathetic outflow, depress vagal tone, and contribute to orthostatic intolerance. Low vagal tone removes the cholinergic brake on mast cells, creating a self-amplifying loop between autonomic dysfunction and mast cells. Workup includes Beighton score and 2017 hEDS criteria; 10-minute active stand test for BP and HR (tilt-table if borderline); mast cell mediator panel (tryptase, plasma histamine, urinary N-methylhistamine, prostaglandin D2 metabolites); 1–2 week HRV trend; iron, ferritin, B12, vitamin D levels; echocardiogram to rule out vascular EDS and assess mitral valve. Sequenced treatment: 1. POTS first (most reversible): 2.5–3 L water, 8–10 g sodium daily; waist-high 20–30 mmHg compression garments; recumbent exercise; ivabradine, midodrine, or low-dose beta-blockade if needed. 2. Mast cell stabilization: H1 + H2 antihistamines, cromolyn sodium, quercetin, luteolin; identify/remove triggers without restriction trap. 3. Vagal tone restoration: slow breathing protocols, HRV biofeedback, transcutaneous auricular vagus nerve stimulation (modulates autonomic and mast cell axes via cholinergic anti-inflammatory pathway). 4. Connective tissue/mitochondria support: vitamin C, magnesium, B-complex, CoQ10; protected-range strength training; sleep optimization and pacing. Avoid aggressive end-range stretching/yoga, generic exercise recommendations, restrictive diets without rationale, and 'it's anxiety' framing. Clinical takeaway: Trifecta is mechanistic; treat autonomic state first (modifiable), stabilize mast cells, rebuild vagal tone atop unchangeable connective tissue substrate. https://t.co/JpKlWj7SFl